Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Probing the nature of the χc1(3872)\chi_{c1}(3872) state using radiative decays

The radiative decays $\chi_{c1}(3872)\rightarrow\psi(2S)\gamma$ and $\chi_{c1}(3872)\rightarrow J/\psi\gamma$ are used to probe the~nature of the~$\chi_{c1}(3872)$ state using proton-proton collision data collected with the LHCb detector, corresponding to an~integrated luminosity of~9fb$^{-1}$. Using the~$B^+\rightarrow \chi_{c1}(3872)K^+$decay, the $\chi_{c1}(3872)\rightarrow \psi(2S)\gamma$ process is observed for the first time and the ratio of its partial width to that of the $\chi_{c1}(3872)\rightarrow J/\psi\gamma$ decay is measured to be $$\frac{\Gamma_{\chi_{c1}(3872)\rightarrow \psi(2S)\gamma}} {\Gamma_{\chi_{c1}(3872)\rightarrow J/\psi\gamma}} = 1.67 \pm 0.21 \pm 0.12 \pm0.04 ,$$ where the first uncertainty is statistical, the second systematic and the third is due to the uncertainties on the branching fractions of the $\psi(2S)$ and $J/\psi$ mesons. The measured ratio makes the interpretation of the $\chi_{c1}(3872)$ state as a~pure $D^0\bar{D}^{*0}+\bar{D}^0D^{*0}$ molecule questionable and strongly indicates a sizeable compact charmonium or tetraquark component within the $\chi_{c1}(3872)$ state.Comment: 31 pages, 2 figures. All figures and tables, along with any supplementary material and additional information, are available at https://cern.ch/lhcbproject/Publications/p/LHCb-PAPER-2024-015.html (LHCb public pages

Measurement of Energy Correlators inside Jets and Determination of the Strong Coupling Formula Presented

Energy correlators that describe energy-weighted distances between two or three particles in a hadronic jet are measured using an event sample of $\sqrt{s}$=13 TeV proton-proton collisions collected by the CMS experiment and corresponding to an integrated luminosity of 36.3 fb$^{−1}$. The measured distributions are consistent with the trends in the simulation that reveal two key features of the strong interaction: confinement and asymptotic freedom. By comparing the ratio of the measured three- and two-particle energy correlator distributions with theoretical calculations that resum collinear emissions at approximate next-to-next-to-leading-logarithmic accuracy matched to a next-to-leading-order calculation, the strong coupling is determined at the Z boson mass: α$_S$ (m$_Z$)=0.1229 $\frac{0.0040}{-0.0050}$ , the most precise α$_S$m$_Z$ value obtained using jet substructure observable

Search for resonance-enhanced CP and angular asymmetries in the Λc+→pμ+μ− decay at LHCb

The first measurement of the CP asymmetry of the decay rate (ACP) and the CP average (ΣAFB) and CP asymmetry (ΔAFB) of the forward-backward asymmetry in the muon system of Λþ c → pμþμ− decays is reported. The measurement is performed using a data sample of proton-proton collisions, recorded by the LHCb experiment from 2016 to 2018 at a center-of-mass energy of 13 TeV, which corresponds to an integrated luminosity of 5.4 fb−1. The asymmetries are measured in two regions of dimuon mass near the φ-meson mass peak. The dimuon-mass integrated results are ACP 1⁄4 ð−1.1 4.0 0.5Þ%, ΣAFB 1⁄4 ð3.9 4.0 0.6Þ%, ΔAFB 1⁄4 ð3.1 4.0 0.4Þ%, where the first uncertainty is statistical and the second systematic. The results are consistent with the conservation of CP symmetry and the Standard Model expectations

Search for high-mass resonances decaying to a jet and a Lorentz-boosted resonance in proton-proton collisions at s=13TeV

A search is reported for high-mass hadronic resonances that decay to a parton and a Lorentz-boosted resonance, which in turn decays into a pair of partons. The search is based on data collected with the CMS detector at the LHC in proton-proton collisions at root s = 13 TeV, corresponding to an integrated luminosity of 138 fb(-1). The boosted resonance is reconstructed as a single wide jet with substructure consistent with a two-body decay. The high-mass resonance is thus considered as a dijet system. The jet substructure information and the kinematic properties of cascade resonance decays are exploited to disentangle the signal from the large quantum chromodynamics multijet background. The dijet mass spectrum is analyzed for the presence of new high-mass resonances, and is found to be consistent with the standard model background predictions. Results are interpreted in a warped extra dimension model where the high-mass resonance is a Kaluza-Klein gluon, the boosted resonance is a radion, and the final state partons are all gluons. Limits on the production cross section are set as a function of the Kaluza-Klein gluon and radion masses. These limits exclude at 95% confidence level models with Kaluza-Klein gluon masses in the range 2.0 to 4.3 TeV and radion masses in the range 0.20 to 0.74TeV. By exploring a novel experimental signature, the observed limits on the Kaluza-Klein gluon mass are extended by up to about 1 TeV compared to previous searches. (C) 2022 The Author(s). Published by Elsevier B.V

Proton reconstruction with the CMS-TOTEM Precision Proton Spectrometer

The Precision Proton Spectrometer (PPS) of the CMS and TOTEM experiments collected 107.7 fb-1 in proton-proton (pp) collisions at the LHC at 13 TeV (Run 2). This paper describes the key features of the PPS alignment and optics calibrations, the proton reconstruction procedure, as well as the detector efficiency and the performance of the PPS simulation. The reconstruction and simulation are validated using a sample of (semi)exclusive dilepton events. The performance of PPS has proven the feasibility of continuously operating a near-beam proton spectrometer at a high luminosity hadron collider

Search for D0 meson decays to π+π−e+e− and K+K−e+e− final states

A search for D0 meson decays to the πþπ−eþe− and KþK−eþe− final states is reported using a sample of proton-proton collisions collected by the LHCb experiment at a center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 6 fb−1. The decay D0 → πþπ−eþe− is observed for the first time when requiring that the two electrons are consistent with coming from the decay of a φ or ρ0=ω meson. The corresponding branching fractions are measured relative to the D0 → K−π−1⁄2eþe−ρ0=ω decay, where the two electrons are consistent with coming from the decay of a ρ0 or ω meson. No evidence is found for the D0 → KþK−eþe− decay and world-best limits are set on its branching fraction. The results are compared to, and found to be consistent with, the branching fractions of the D0 → πþπ−μþμ− and D0 → KþK−μþμ− decays recently measured by LHCb and confirm lepton universality at the current precision

Test of Lepton Flavor Universality with B+→K+π+π−l+l− Decays

The first test of lepton flavor universality between muons and electrons using Bþ → Kþπþπ−lþl− (l 1⁄4 e, μ) decays is presented. The measurement is performed with data from proton-proton collisions collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV, corresponding to an integrated luminosity of 9 fb−1. The ratio of branching fractions between Bþ → Kþπþπ−eþe− and Bþ → Kþπþπ−μþμ− decays is measured in the dilepton invariant-mass-squared range 1.1 &lt; q2 &lt; 7.0 GeV2=c4 and is found to be R−1 Kππ 1⁄4 1.31þ0.18 −0.17 ðstatÞ þ0.12 −0.09 ðsystÞ, in agreement with the standard model prediction. The first observation of the Bþ → Kþπþπ−eþe− decay is also reporte